Promotion of sleep by targeting the orexin system in rats, dogs and humans

Nature Medicine

Volumn 13, Issue 2, 2007, Pages 150-155

  Brisbare Roch, Catherine ^a   Dingemanse, Jasper ^a   Koberstein, Ralf ^a   Hoever, Petra ^a   Aissaoui, Hamed ^a   Flores, Susan ^a   Mueller, Celia ^a   Nayler, Oliver ^a   Van Gerven, Joop ^b   De Haas, Sanne L ^b   Hess, Patrick ^a   Qiu, Changbin ^c   Buchmann, Stephan ^a   Scherz, Michael ^a   Weller, Thomas ^a   Fischli, Walter ^a   Clozel, Martine ^a   Jenck, François ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; [2 [6,7 DIMETHOXY 1 [2 (4 TRIFLUOROMETHYLPHENYL)ETHYL] 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL] N METHYL 2 PHENYLACETAMIDE]; OREXIN; OREXIN 1 RECEPTOR; OREXIN 2 RECEPTOR; RECEPTOR BLOCKING AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; ZOLPIDEM;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CATAPLEXY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOG; ELECTROPHYSIOLOGY; HUMAN; HUMAN EXPERIMENT; HUMAN VERSUS ANIMAL COMPARISON; MALE; NARCOLEPSY; NONHUMAN; NONREM SLEEP; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; RAT; RECEPTOR BLOCKING; REM SLEEP; SLEEP INDUCTION;

ACETAMIDES; ANIMALS; DOGS; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; HYPOTHALAMUS, POSTERIOR; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; ISOQUINOLINES; MALE; NEUROPEPTIDES; RATS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SEX FACTORS; SIGNAL TRANSDUCTION; SLEEP, REM; TETRAHYDROISOQUINOLINES;

CANIS FAMILIARIS; MAMMALIA; RATTUS; RODENTIA;

EID: 33846979755     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm1544     Document Type: Article

References (42)

1. de Lecea, L. et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc. Natl. Acad. Sci. USA 95, 322-327 (1998).
2. Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573-585 (1998).
3. Peyron, C. et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci. 18, 9996-10015 (1998).
4. Nambu, T. et al. Distribution of orexin neurons in the adult rat brain. Brain Res. 827, 243-260 (1999).
5. Kilduff, T.S. & Peyron, C. The hypocretin/orexin ligand-receptor system: implications for sleep and sleep disorders. Trends Neurosci. 23, 359-365 (2000).
6. Lee, M.G., Hassani, O.K. & Jones, B.E. Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J. Neurosci. 25, 6716-6720 (2005).
7. Taheri, S. et al. Diurnal variation in orexin A immunoreactivity and prepro-orexin mRNA in the rat central nervous system. Neurosci. Lett. 279, 109-112 (2000).
8. Yoshida, Y. et al. Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur. J. Neurosci. 14, 1075-1081 (2001).
9. Kiyashchenko, L.I. et al. Release of hypocretin (orexin) during waking and sleep states. J. Neurosci. 22, 5282-5286 (2002).
10. Martinez, G.S., Smale, L. & Nunez, A.A. Diurnal and nocturnal rodents show rhythms in orexinergic neurons. Brain Res. 955, 1-7 (2002).
11. Salomon, R.M. et al. Diurnal variation of cerebrospinal fluid hypocretin-1 (orexin-A) levels in control and depressed subjects. Biol. Psychiatry 54, 96-104 (2003).
12. Zeitzer, J.M. et al. Circadian and homeostatic regulation of hypocretin in a primate model: implications for the consolidation of wakefulness. J. Neurosci. 23, 3555-3560 (2003).
13. Desarnaud, F. et al. The diurnal rhythm of hypocretin in young and old F344 rats. Sleep 27, 851-856 (2004).
14. Hagan, J.J. et al. Orexin A activates locus coeruleus cell firing and increases arousal in the rat. Proc. Natl. Acad. Sci. USA 96, 10911-10916 (1999).
15. Bourgin, P. et al. Hypocretin-1 modulates rapid eye movement sleep through activation of locus coeruleus neurons. J. Neurosci. 20, 7760-7765 (2000).
16. Piper, D.C., Upton, N., Smith, M.I. & Hunter, A.J. The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats. Eur. J. Neurosci. 12, 726-730 (2000).
17. Espana, R.A., Baldo, B.A., Kelley, A.E. & Berridge, C.W. Wake-promoting and sleep-suppressing actions of hypocretin (orexin): basal forebrain sites of action. Neuroscience 106, 699-715 (2001).
18. Kiyashchenko, L.I., Mileykovskiy, B.Y., Lai, Y.Y. & Siegel, J.M. Increased and decreased muscle tone with orexin (hypocretin) microinjections in the locus coeruleus and pontine inhibitory area. J. Neurophysiol. 85, 2008-2016 (2001).
19. Ishibashi, M. et al. Effects of orexins/hypocretins on neuronal activity in the paraventricular nucleus of the thalamus in rats in vitro. Peptides 26, 471-481 (2005).
20. Lambe, E.K., Olausson, P., Horst, N.K., Taylor, J.R. & Aghajanian, G.K. Hypocretin and nicotine excite the same thalamocortical synapses in prefrontal cortex: correlation with improved attention in rat. J. Neurosci. 25, 5225-5229 (2005).
21. Mileykovskiy, B.Y., Kiyashchenko, L.I. & Siegel, J.M. Behavioral correlates of activity in identified hypocretin/orexin neurons. Neuron 46, 787-798 (2005).
22. Estabrooke, I.V. et al. Fos expression in orexin neurons varies with behavioral state. J. Neurosci. 21, 1656-1662 (2001).
23. Chemelli, R.M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437-451 (1999).
24. Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 98, 365-376 (1999).
25. Hara, J. et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30, 345-354 (2001).
26. Nishino, S., Ripley, B., Overeem, S., Lammers, G.J. & Mignot, E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 355, 39-40 (2000).
27. Peyron, C. et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat. Med. 6, 991-997 (2000).
28. Bond, A. & Lader, M. The use of analogue scales in rating subjective feelings. Br. J. Med. Psychol. 47, 211-218 (1974).
29. Kimoff, R.J. et al. Canine model of obstructive sleep apnea: model description and preliminary application. J. Appl. Physiol. 76, 1810-1817 (1994).
30. Ida, T., Nakahara, K., Katayama, T., Murakami, N. & Nakazato, M. Effect of lateral cerebroventricular injection of the appetite-stimulating neuropeptide, orexin and neuropeptide Y, on the various behavioral activities of rats. Brain Res. 821, 526-529 (1999).
31. Methippara, M.M., Alam, M.N., Szymusiak, R. & McGinty, D. Effects of lateral preoptic area application of orexin-A on sleep-wakefulness. Neuroreport 11, 3423-3426 (2000).
32. Xi, M.C., Morales, F.R. & Chase, M.H. Effects on sleep and wakefulness of the injection of hypocretin-1 (orexin-A) into the laterodorsal tegmental nucleus of the cat. Brain Res. 901, 259-264 (2001).
33. Thakkar, M.M. et al. REM sleep enhancement and behavioral cataplexy following orexin (hypocretin)-II receptor antisense perfusion in the pontine reticular formation. Sleep Res. Online 2, 112-120 (1999).
34. Smith, M.I., Piper, D.C., Duxon, M.S. & Upton, N. Evidence implicating a role for orexin-1 receptor modulation of paradoxical sleep in the rat. Neurosci. Lett. 341, 256-258 (2003).
35. Gerashchenko, D. et al. Hypocretin-2-saporin lesions of the lateral hypothalamus produce narcoleptic-like sleep behavior in the rat. J. Neurosci. 21, 7273-7283 (2001).
36. Willie, J.T. et al. Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: molecular genetic dissection of non-REM and REM sleep regulatory processes. Neuron 38, 715-730 (2003).
37. Mieda, M. et al. Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc. Natl. Acad. Sci. USA 101, 4649-4654 (2004).
38. Crocker, A. et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 65, 1184-1188 (2005).
39. Borbely, A.A. From slow waves to sleep homeostasis: new perspectives. Arch. Ital. Biol. 139, 53-61 (2001).
40. van Steveninck, F. Methods of Assessment of Central Nervous System Effects of Drugs in Man. Thesis, Leiden University, (1993).
41. Roehrs, T. & Roth, T. Multiple Sleep Latency Test: technical aspects and normal values. J. Clin. Neurophysiol. 9, 63-67 (1992).
42. Thorpy, M.J. The clinical use of the Multiple Sleep Latency Test. The Standards of Practice Committee of the American Sleep Disorders Association. Sleep 15, 268-276 (1992).